NASDAQ: CELC - Celcuity Inc.

Lønnsomhet i seks måneder: -37.42%
Utbytte: 0.00%
Sektor: Healthcare

Kampanjeplan Celcuity Inc.

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet Celcuity Inc.

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.

flere detaljer
Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

IPO date 2017-09-20
ISIN US15102K1007
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.celcuity.com
Цена ао 10.44
Prisendring per dag: +2.05% (9.75)
Prisendring per uke: +21.19% (8.21)
Prisendring per måned: -0.7976% (10.03)
Prisendring over 3 måneder: -5.51% (10.53)
Prisendring over seks måneder: -37.42% (15.9)
Prisendring per år: -45% (18.09)
Prisendring over 3 år: +32.31% (7.52)
Prisendring over 5 år: +57.94% (6.3)
Prisendring siden begynnelsen av året: -20.53% (12.52)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 0 0
P/BV 2.54 6
P/E 0 0
EV/EBITDA -5.47 0
Total: 3

Effektivitet

Navn Betydning Karakter
ROA, % -33.35 0
ROE, % -45.63 0
Total: 0

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA -0.5632 10
Total: 10

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % 0 0
Lønnsomhet Ebitda, % 687.97 10
Lønnsomhet EPS, % 292.34 10
Total: 8
Flere detaljer

Institusjoner Volum Dele, %
Morgan Stanley 2195179 7.21
Soleus Capital Management, L.P. 2179481 7.16
VR Adviser, LLC 1885538 6.19
COMMODORE CAPITAL LP 1754704 5.76
Perceptive Advisors LLC 1481300 4.86
NEA Management Company, LLC 1250001 4.1
Blackrock Inc. 1050391 3.45
Vanguard Group Inc 820776 2.7
CapTrust Financial Advisors 544835 1.79
Baker Brothers Advisors, LLC 535478 1.76

ETFDele, %Lønnsomhet for året, %Utbytte, %
Jacob Forward ETF 0.85997 43.03 0.15284
iShares Morningstar Small-Cap Growth ETF 0.00891 596.94 0.72598
iShares Morningstar Small-Cap ETF 0.00435 391.25 1.60498
0.29343.740.83



Veileder Stillingstittel Betaling Fødselsår
Mr. Brian F. Sullivan Co-Founder, Chairman & CEO 478.12k 1962 (63 år)
Dr. Lance G. Laing Ph.D. Co-Founder, Chief Science Officer, VP, Secretary & Director 389.55k 1962 (63 år)
Ms. Vicky Hahne Chief Financial Officer 281.59k 1966 (59 år)
Dr. John R. MacDonald Dabt, Ph., Ph.D. Senior Vice President of R&D N/A 1955 (70 år)
Ms. Sheri Smith Acting Head of Clinical Operations N/A
Mr. Igor Gorbatchevsky M.D. Chief Medical Officer N/A
Mr. Eldon C. Mayer III, M.B.A. Chief Commercial Officer N/A 1961 (64 år)
Dr. Charlotte Moser M.B.A., M.D., M.Sc., Ph.D. Senior Vice President of Clinical Development

Adresse: United States, Minneapolis. MN, 16305–36th Avenue North - åpne i Google maps, åpne Yandex-kart
Nettsted: https://www.celcuity.com